Page last updated: 2024-11-13
4-hydroxyospemifene
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 22504506 |
| SCHEMBL ID | 5738276 |
| MeSH ID | M0573295 |
Synonyms (8)
| Synonym |
|---|
| SCHEMBL5738276 |
| ospemifene metabolite m1 |
| (z)-4-(1-(2-chloroethyl)-2-(4-(2-hydroxyethoxy)phenyl)-2-phenylvinyl)phenol |
| MZC9KS3HJL , |
| 341525-22-2 |
| phenol, 4-((4z)-3-chloro-1-((4-(2-hydroxyethoxy)phenyl)phenylmethylene)propyl)- |
| 4-hydroxyospemifene |
| unii-mzc9ks3hjl |
Research Excerpts
Pharmacokinetics
| Excerpt | Reference | Relevance |
|---|---|---|
| "The clinical pharmacokinetic findings and in vitro data suggest that CYP3A4 is important for ospemifene metabolism, but other CYP isoforms and metabolic pathways also contribute." | ( Effects of cytochrome P450 inhibitors and inducers on the metabolism and pharmacokinetics of ospemifene. Lammintausta, R; Lehtinen, T; Pelkonen, O; Scheinin, M; Tolonen, A; Turpeinen, M; Uusitalo, J; Vuorinen, J, 2013) | 0.39 |
Bioavailability
| Excerpt | Reference | Relevance |
|---|---|---|
| "To assess the effect of concomitant food intake on the relative bioavailability of ospemifene and its main metabolite, 4-hydroxyospemifene, after single oral dosing." | ( Oral bioavailability of ospemifene improves with food intake. Aaltonen, AM; Katila, K; Koskimies, P; Lammintausta, R; Saarni, O; Scheinin, M; Vuorinen, J, 2013) | 0.6 |
| " The increase in bioavailability was not linearly related with the fat content of the meal." | ( Oral bioavailability of ospemifene improves with food intake. Aaltonen, AM; Katila, K; Koskimies, P; Lammintausta, R; Saarni, O; Scheinin, M; Vuorinen, J, 2013) | 0.39 |
Dosage Studied
| Excerpt | Relevance | Reference |
|---|---|---|
| " In this study, we test the effects of three dosing levels of ospemifene in both the prevention and treatment of breast cancer in the MTag." | ( Ospemifene and 4-hydroxyospemifene effectively prevent and treat breast cancer in the MTag.Tg transgenic mouse model. Bell, KE; Burich, RA; DeGregorio, MW; Greenberg, BE; Griffey, SM; McCall, JL; Mehta, NR; Wurz, GT, 2012) | 0.73 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (5)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 12.43
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.43) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 2 (40.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 3 (60.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||